Aigen Investment Management, LP Fate Therapeutics Inc Transaction History

Aigen Investment Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$2.02 - $5.04 $86,451 - $215,701	42,798 New	42,798 $90,000
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $150,235 - $394,014	35,433 New	35,433 $201,000
Q1 2021 May 11, 2021	SELL	$72.16 - $117.4 $518,541 - $843,636	-7,186 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$38.09 - $100.95 $273,714 - $725,426	7,186 New	7,186 $653,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $220M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.